Labcorp推出新的測試，以加快阿爾茨海默氏病的診斷路徑

阿爾茨海默病是最常見的癡呆症。據美國疾病控製和預防中心(CDC), 多達670萬美國人患有老年癡呆症，預計到2060年，這一數字將翻一番，達到1400萬人。
今天，我們推出了新的ATN簡介，這是一個重要的裏程碑。這項首創的研究結合了三種經過充分研究的血液生物標誌物測試，以識別和評估與阿爾茨海默病相關的生物學變化——澱粉樣蛋白斑、tau蛋白纏結和神經退行性病變（ATN）。
ATN Profile可在全國範圍內使用，用於根據臨床觀察和認知篩查評估可能的阿爾茨海默病或其他認知障礙原因的患者。該測試旨在幫助縮短診斷和幹預的時間。神經學家和其他醫療保健提供者可以訂購這種測試，以幫助他們決定是否將病人轉介到專家。
據Brian Caveney，醫學博士，執行副總裁和總裁，早期發展研究實驗室和首席醫療和科學官，“許多患者經曆周圍的阿爾茨海默氏病的風險的不確定性，這可能需要幾個月甚至幾年的診斷。更明確的測試，包括我們新的ATN簡介，可以為病人，他們的親人，以及在他們指導治療和治療過程中治療醫生提供客觀的見解。”
在Labcorp，我們仍然致力於改善受阿爾茨海默氏症影響的人的健康和生活，並將繼續投資於治療和管理疾病的研究和藥物開發。

 

 

 

 

 

Alzheimer’s disease is the most common form of dementia. According to the U.S. Centers for Disease Control and Prevention (CDC), as many as 6.7 million Americans are living with Alzheimer’s, a number that is expected to more than double to 14 million people by 2060.

Today, we marked a major milestone by launching our new ATN Profile. This first-of-its-kind profile combines three well-researched blood biomarker tests to identify and assess biological changes associated with Alzheimer’s disease – amyloid plaques, tau tangles and neurodegeneration (ATN).

The ATN Profile is available nationwide for use with patients being evaluated for possible Alzheimer’s disease or other causes of cognitive impairment based on clinical observation and cognitive screenings. The test is intended to help shorten the time to diagnosis and intervention. Neurologists and other healthcare providers can order this test to help them decide whether to refer a patient to a specialist.

According to Brian Caveney, M.D., EVP and President, Early Development Research Laboratories and Chief Medical and Scientific Officer, “Many patients experience uncertainty around Alzheimer’s disease risk, which can take months or even years to diagnose. More definitive testing, including our new ATN Profile, can provide objective insights to patients, their loved ones, and treating physicians as they navigate care and treatment.”

At Labcorp, we remain committed to improving the health and lives of those impacted by Alzheimer’s and will continue to invest in studies and drug development to treat and manage the disease.

所有跟帖： 

• 診斷出來可以治療嗎 -rancho2008- ♀ (0 bytes) () 10/13/2023 postreply 10:39:57

• 確切的引起阿爾茨海默病機理目前還沒整明白. -5181- ♂ (0 bytes) () 10/13/2023 postreply 16:48:03

• 對神經重要的蛋白不吸收了就出這些毛病了吧。看遊泳池裏腿部萎縮的小男孩真讓人心痛。 -julie116- ♀ (109 bytes) () 10/13/2023 postreply 19:02:37

• 還有某些物質對人體傳電機製的影響 -julie116- ♀ (0 bytes) () 10/14/2023 postreply 09:56:16

• 看到了路透社的報道，Labcorp正在與醫保業者溝通，收費是$626。等等看。 -zillos- ♂ (0 bytes) () 10/13/2023 postreply 21:00:50

• 看看是不是這項： -zillos- ♂ (137 bytes) () 10/13/2023 postreply 21:07:45

• 如果能診斷，就能找到原因，希望早日找到治療的方法。 -goingplace- ♀ (0 bytes) () 10/14/2023 postreply 02:33:33